Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology
Aging Clinical and Experimental Research · 2026
DOI: 10.1007/s40520-026-03391-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Clinical and Experimental Research, 2026. Verfasst von Angelo Semeraro und 8 weiteren Autor:innen. Beteiligte Einrichtung: U.O.S. Reumatologia, P.O. Valle D'Itria, ASL - Taranto, Martina Franca, Italy. angesemeraro62@gmail.com. Hauptthemen laut MEDLINE: Bone Density, Postmenopause, Antibodies, Monoclonal, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Romosozumab/AMG785 (Evenity®, Amgen and UCB pharma, RMZ) is a sclerostin-neutralizing antibody that rapidly increases BMD, but very short-term monitoring in clinical routine is limited by specific issues of available ionizing techniques. AIMS: To assess the effectiveness of the radiation-free Radiofrequency Echographic Multi Spectrometry (REMS) for very short-term monitoring of RMZ in postmenopausal women. METHODS: Seventy-four postmenopausal women starting RMZ and 52 postmenopausal women not receiving anti-osteoporosis drugs underwent proximal femur REMS scans at baseline and after 6 months, assessing total hip (TH) and femoral neck (FN) BMD. Exploratory analyses were also performed in treatment-naïve patients and in women with ≥ 2 prior fragility fractures. RESULTS: After six months of RMZ, BMD significantly increased at both TH (+ 3.7%; 0.718 ± 0.103 g/cm2 vs. 0.698 ± 0.116 g/cm2; p 0.05) or FN (-0.6%; p > 0.05). Weight and BMI did not change significantly over the considered 6-month interval. CONCLUSIONS: REMS detected clinically-relevant 6-month increases in femoral BMD during RMZ therapy, while BMD remained stable in untreated controls. These findings, together with anthropometric stability, support the feasibility of REMS for very short-term follow-up in real-world settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- U.O.S. Reumatologia, P.O. Valle D'Itria, ASL - Taranto, Martina Franca, Italy. angesemeraro62@gmail.com.
- U.O.S. Reumatologia, P.O. Valle D'Itria, ASL - Taranto, Martina Franca, Italy.
- U.O.C. Medicina Generale, P.O. Valle D'Itria, Martina Franca, ASL - Taranto, Italy.
Zitieren
APA
Semeraro, A., Chialà, A., Carafa, A., Fanizzi, R., Di Tano, E., Palmisano, M., Santoro, C., Dibenedetto, F., & Napoli, N. (2026). Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-026-03391-7
Vancouver
Semeraro A, Chialà A, Carafa A, Fanizzi R, Di Tano E, Palmisano M, et al. Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology. Aging Clinical and Experimental Research. 2026. doi:10.1007/s40520-026-03391-7
BibTeX
@article{Semeraro2026,
author = {Semeraro, Angelo and Chialà, Angela and Carafa, Andrea and Fanizzi, Rosalinda and Di Tano, Elisabetta and Palmisano, Maria and Santoro, Carmela and Dibenedetto, Federica and Napoli, Nicola},
title = {Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology},
journal = {Aging Clinical and Experimental Research},
year = {2026},
doi = {10.1007/s40520-026-03391-7}
}
EUVIMED